Making Cell and Gene Therapies Accessible

Cell and gene therapies represent some of the most transformative advances in modern medicine, offering the potential to cure diseases once thought untreatable. Yet their long-term impact depends on more than science alone, it hinges on manufacturability, scalability, and global access. Developing therapies that are both effective and widely available remains one of the industry’s greatest challenges.

Carlos Arbelaez will help lead a high-level panel discussion exploring how the biopharma community can make advanced therapies more scalable, economically viable, and accessible worldwide. Drawing on his experience at Johnson & Johnson, Carlos will guide conversations that connect scientific innovation with practical execution, helping attendees understand how to turn breakthrough science into sustainable solutions.

Panel topics will include:

• Navigating manufacturing complexity – addressing the unique challenges of autologous and allogeneic systems.

• Identifying cost-reduction pathways – exploring strategies to make therapies more economically feasible without compromising quality.

• Coordinating regulatory and supply chain strategies – aligning operations across global markets to ensure timely delivery.

• Preparing for the future commercial landscape – anticipating challenges and opportunities for next-generation modalities.

This session goes beyond scientific advances to tackle strategic execution, providing critical insights for organizations investing in cell and gene therapies. Attendees will leave with a deeper understanding of the operational, regulatory, and economic levers needed to bring transformative therapies from the lab to patients around the world.

Don’t miss this conversation on the future of advanced modalities, where innovation meets implementable strategy, and the promise of next-generation therapies becomes reality.